February 1, 2023 Eric M. Ostertag, M.D., Ph.D. Re: Transition and Consulting Agreement Dear Eric:Transition and Consulting Agreement • March 9th, 2023 • Poseida Therapeutics, Inc. • Biological products, (no disgnostic substances)
This letter sets forth the substance of the transition and consulting agreement (the “Agreement”) that Poseida Therapeutics, Inc. (the “Company”) is offering to you in connection with your employment transition.
January 6, 2022 Brent Warner Delivered via EmailEmployment Agreement • March 9th, 2023 • Poseida Therapeutics, Inc. • Biological products, (no disgnostic substances)
On behalf of Poseida Therapeutics, Inc. (the “Company” or “Poseida”), I am pleased to offer you employment under the terms set forth in this offer letter agreement (the “Agreement”). These employment terms will be effective as of your start date, which is anticipated to be February 21, 2022 (such date your employment actually begins, the “Start Date”).
